MAP1LC3B and benign prostatic hyperplasia: Regarding the expression of the used autophagy markers in BPH in the present study, Beclin1 was expressed in 40% of cases, and LC3B was expressed in 44% of cases, and these results were close to that of Liu et al. (2013) (22) who found that Beclin-1 was expressed in 34.15% of BPH cases and LC3 was expressed in 36.59% of cases.